CARMAT completes €60 million reserved offering for specialized and strategic investors
Client(s) CARMAT SA
Jones Day advised CARMAT SA, a designer and developer of the world's most advanced heart project, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, in connection with its €60 million (US$66.3 million) share capital increase, reserved for investors, specialists of the healthcare and life sciences industry, or strategic partners of CARMAT.